PT - JOURNAL ARTICLE AU - Staaf, Johan AU - Häkkinen, Jari AU - Hegardt, Cecilia AU - Saal, Lao H AU - Kimbung, Siker AU - Hedenfalk, Ingrid AU - Lien, Tonje AU - Sørlie, Therese AU - Naume, Bjørn AU - Russnes, Hege AU - Marcone, Rachel AU - Ayyanan, Ayyakkannu AU - Brisken, Cathrin AU - Malterling, Rebecka R. AU - Asking, Bengt AU - Olofsson, Helena AU - Lindman, Henrik AU - Bendahl, Pär-Ola AU - Ehinger, Anna AU - Larsson, Christer AU - Loman, Niklas AU - Rydén, Lisa AU - Malmberg, Martin AU - Borg, Åke AU - Vallon-Christersson, Johan TI - RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer AID - 10.1101/2021.12.03.21267116 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.03.21267116 4099 - http://medrxiv.org/content/early/2021/12/17/2021.12.03.21267116.short 4100 - http://medrxiv.org/content/early/2021/12/17/2021.12.03.21267116.full AB - Background Multigene expression assays for molecular subtypes and biomarkers can aid clinical management of early invasive breast cancer (IBC). Based on RNA-sequencing we aimed to develop robust single-sample predictor (SSP) models for conventional clinical markers as well as molecular intrinsic subtype and risk of recurrence (ROR) that provide clinically relevant prognostic stratification.Methods A uniformly accrued breast cancer cohort of 7743 patients with RNA-sequencing data from fresh tissue was divided into a training set (n=5250) and a reserved test set (n=2412). We trained SSPs for PAM50 molecular subtypes and ROR assigned by nearest-centroid (NC) methods and SSPs for conventional clinical markers from histopathology data. Additionally, SSP classifications were compared with Prosigna in two external cohorts (ABiM, n=100 and OSLO2-EMIT0, n=103). Prognostic value was assessed using distant recurrence-free interval (DRFi).Results In the test set, agreement between SSP and NC classifications for PAM50 (five subtypes) and Subtype (four subtypes) was high (85%, Kappa=0.78) and very high (90%, Kappa=0.84) respectively. Accuracy for ROR risk category was high (84%, Kappa=0.75, weighted Kappa=0.90). The prognostic value for SSP and NC classification was assessed as equivalent and added clinically relevant prognostic information. Agreement for SSP and histopathology was very high or high for receptor status, while moderate and poor for Ki67 status and Nottingham histological grade, respectively. SSP concordance with Prosigna was high for subtype (OSLO 83% and ABiM 80%, Kappa=0.73 and 0.72, respectively) and moderate and high for ROR risk category (68% and 84%, Kappa=0.50 and 0.70, weighted Kappa=0.70 and 0.78). In pooled analysis, concordance between SSP and Prosigna for emulated treatment recommendation dichotomized for chemotherapy (yes vs. no) was high (85%, Kappa=0.66). In postmenopausal ER+/HER2-/N0 patients SSP application suggested changed treatment recommendations for up to 17% of patients, with nearly balanced escalation and de-escalation of chemotherapy.Conclusions Robust SSP models, mimicking histopathological variables, PAM50, and ROR classifications can be derived from RNA-sequencing that closely matches clinical tests. Agreement and DRFi analyses suggest that NC and SSP models are interchangeable on a group-level and nearly so on a patient level. Retrospective evaluation in ER+/HER2-/N0 IBC suggested that molecular testing could lead to a changed therapy recommendation for almost one-fifth of patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support for this study was provided by the Swedish Cancer Society (CAN 2016/659, CAN 2018/685 CAN 2021/1407 and a 2018 Senior Investigator Award [JS: SIA190013]), the Mrs Berta Kamprad Foundation (FBKS 2018-3, FBKS-2020-5 and FBKS-2020-9), the Lund-Lausanne L2-Bridge/Biltema Foundation (F 2016/1330), the Mats Paulsson Foundation (IACD 2017), and Swedish governmental funding (ALF, grant 2018/40612). Work on the ABiM cohort was supported by Bröstcancerförbundet. The OSLO2-EMIT0 was funded by grants from The Norwegian Cancer Society (420056), South-Eastern Norway Regional Health Authority (2012071) and open access funding provided by Oslo University Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given for the included SCAN-B study material (approval numbers 2009/658, 2010/383, 2012/58, 2013/459 and 2015/277) and ethical approval was given for the included ABiM study material (approval number 2007/155) by the Regional Ethical Review Board in Lund, Sweden, governed by the Swedish Ethical Review Authority, Box 2110, 750 02 Uppsala, Sweden. Ethical approval was given for the included normal breast tissue obtained from women undergoing mammoplasty surgery by the Cantonal ethics committee, Commission Cantonale d éthique de la recherche sur l être humain, CER-VD, Avenue de Chailly, 1012 Lausanne, Switzerland (Approval number 183/10). Ethical approval was given for the included OSLO2-EMIT0 study material (approval number 29668) by the Norwegian South-East Regional Committee for Medical and Health Research Ethics, Postboks 1130, Blindern, 0318 Oslo, Norway.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be made available upon reasonable request to the authors or online upon peer-reviewed publication.